intepirdine   Click here for help

GtoPdb Ligand ID: 9444

Synonyms: RVT-101 | SB-742457
Compound class: Synthetic organic
Comment: Intepirdine (RVT-101) is a 5-HT6 receptor antagonist [4] (called SB-742457 in this article). Developed by Axovant Science Ltd.
Phase 3 clinical trial results for RVT-101 are eagerly awaited given the reported failures of competitors' 5-HT6 receptor antagonists in Alzheimer's disease trials (e.g. Lundbeck's idalopirdine, and Pfizer's PF-05212377).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 70.68
Molecular weight 353.12
XLogP 2.83
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=S(=O)(c1cnc2c(c1)cccc2N1CCNCC1)c1ccccc1
Isomeric SMILES O=S(=O)(c1cnc2c(c1)cccc2N1CCNCC1)c1ccccc1
InChI InChI=1S/C19H19N3O2S/c23-25(24,16-6-2-1-3-7-16)17-13-15-5-4-8-18(19(15)21-14-17)22-11-9-20-10-12-22/h1-8,13-14,20H,9-12H2
InChI Key JJZFWROHYSMCMU-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Intepirdine (RVT-101) is in Phase 3 clinical trial in Alzheimer's patients (link to ClinicalTrials.gov's full list of RVT-101 trials here). The studies are designed to evaluate intepirdine-induced restoration of cognition and functional impairments in the target populations. Efficacy of 5-HT6 antagonism in conjunction with cholinesterase inhibition (donepezil) is included in these studies. Phase 2 data are reported in [6] (as a single agent) and [5] (in combination with donepezil).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The rationale for use of 5-HT6 receptor antagonists in AD is discussed in [2] and [7].